Parkman Healthcare Partners LLC Has $6.08 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Parkman Healthcare Partners LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 109,468 shares of the biopharmaceutical company’s stock after purchasing an additional 9,468 shares during the period. Parkman Healthcare Partners LLC owned 0.12% of Ultragenyx Pharmaceutical worth $6,081,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $691,000. DNB Asset Management AS raised its stake in shares of Ultragenyx Pharmaceutical by 29.1% during the second quarter. DNB Asset Management AS now owns 12,942 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 2,921 shares during the last quarter. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical in the second quarter valued at approximately $653,000. Wealth Enhancement Advisory Services LLC boosted its stake in Ultragenyx Pharmaceutical by 15.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 7,359 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 975 shares during the last quarter. Finally, Oak Ridge Investments LLC acquired a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth $795,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.80% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Down 2.0 %

Shares of RARE stock opened at $46.67 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The company’s fifty day simple moving average is $51.63 and its 200-day simple moving average is $48.79. The firm has a market cap of $4.31 billion, a PE ratio of -7.21 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.23) EPS. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. TD Cowen lifted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. lowered their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 21st. Finally, HC Wainwright lifted their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.